Sign inJoin waitlistJoin the waitlist

Sameek Roychowdhury

Professor · Ohio State University Hospital

Credentials: · · · · ·

History

Ohio State University Hospital
Present

Medical Oncology
2009–2011
Internal Medicine
University of Michigan
2006–2009
Ohio State University College of Medicine
2002–2006

Research

Landscape of Microsatellite Instability Across 39 Cancer Types
JCO Precision Oncology · 2017 · Last of 9 authors · 1,256 citations
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Nature Genetics · 2013 · 922 citations
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing
Nature Genetics · 2013 · 632 citations

Aharon Freud
16 papers
Hui-Zi Chen
13 papers · 9 as a fellow
MC
Michael Caligiuri
13 papers
RB
Russell Bonneville
12 papers · 1 as a resident
Robert Baiocchi
9 papers · 8 as a fellow
CE
Charles Eisenbeis
6 papers · 2 as a fellow
John Hays
6 papers
MT
Moshe Talpaz
6 papers
Kenneth Pienta
5 papers
Milind Javle
5 papers
PA
Patricia Allenby
5 papers
Senthil Damodaran
5 papers

Grants

Clinical Validation of FGFR-Dx in Plasma Cell-Free DNA from Patients with FGFR-Altered Advanced Pancreatic Cancer
National Cancer Institute · UH3
Contact PI · $327K · Ohio State University
2026–2029
Liquid Biopsy for Rapid Detection and Real Time Monitoring of FGFR-Altered Cancers
National Cancer Institute · UH3
Contact PI · $957.4K · Ohio State University
2021–2026
Liquid Biopsy for Rapid Detection and Real Time Monitoring of FGFR-Altered Cancers
National Cancer Institute · UH2
Contact PI · $357.2K · Ohio State University
2021–2023
Detection of Microsatellite Instability Biomarkers for Therapeutic Clinical Trial Eligibility
National Cancer Institute · UH3
Contact PI · $942K · Ohio State University
2017–2022

Clinical trials

Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
Principal investigator · Recruiting · Phase 2
Ohio State University Comprehensive Cancer Center
2026–2027
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Principal investigator · Recruiting · Phase 2
Sameek Roychowdhury
2025–2028
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
Principal investigator · Completed · Phase 2
Sameek Roychowdhury
2020–2024
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
Principal investigator · Withdrawn · Phase 2
Sameek Roychowdhury
2019–2021